Glaukos ROI - Return on Investment 2014-2024 | GKOS

Glaukos return on investment for the quarter ending September 30, 2024 was -18.71.

  • Glaukos average return on investment for 2023 was -15.37, a 104.66% increase from 2022.
  • Glaukos average return on investment for 2022 was -7.51, a 5.92% increase from 2021.
  • Glaukos average return on investment for 2021 was -7.09, a 31.83% increase from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.

Glaukos ROI - Return on Investment 2014-2024 | GKOS

  • Glaukos average return on investment for 2023 was -15.37, a 104.66% increase from 2022.
  • Glaukos average return on investment for 2022 was -7.51, a 5.92% increase from 2021.
  • Glaukos average return on investment for 2021 was -7.09, a 31.83% increase from 2020.

Roi - return on investment can be defined as an indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$196.3B
Intuitive Surgical (ISRG)$195.1B
Alcon (ALC)$42.4B
Edwards Lifesciences (EW)$41.6B
IQVIA Holdings (IQV)$36.6B
IDEXX Laboratories (IDXX)$34.2B
DexCom (DXCM)$28.4B
Waters (WAT)$22.2B
STERIS (STE)$21.2B
SONOVA HOLDING (SONVY)$20.8B
Hologic (HOLX)$18.3B
Fresenius Medical Care AG KGaA (FMS)$13B
Sysmex ADR (SSMXY)$12.9B
Globus Medical (GMED)$11.5B
Penumbra (PEN)$9.4B
Masimo (MASI)$9.3B
Teleflex (TFX)$8.9B
PROCEPT BioRobotics (PRCT)$4.9B
Integer Holdings (ITGR)$4.6B
Veracyte (VCYT)$3.1B
Inari Medical (NARI)$2.9B
LivaNova (LIVN)$2.8B
TransMedics (TMDX)$2.6B
Nihon Kohden (NHNKY)$2.5B
Elekta AB (EKTAY)$2.2B
Tandem Diabetes Care (TNDM)$2B
Integra LifeSciences Holdings (IART)$1.8B
RxSight (RXST)$1.8B
Alphatec Holdings (ATEC)$1.4B
Artivion (AORT)$1.2B